Preconditioning-mediated neuroprotection through erythropoietin?
Dawson
Ted M
TM
Institute for Cellular Engineering, Department of Neurology and Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA. tdawson@jhmi.edu
D004921:Erythropoietin / Q000494:pharmacology / Q000502:physiology* / Q000627:therapeutic use*; D006801:Humans; D019194:Ischemic Preconditioning / Q000009:adverse effects* / Q000379:methods*; D053614:Janus Kinase 2; D016328:NF-kappa B / Q000187:drug effects / Q000502:physiology; D019636:Neurodegenerative Diseases / Q000628:therapy*; D018696:Neuroprotective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D009569:Nitric Oxide / Q000502:physiology; D011505:Protein-Tyrosine Kinases / Q000187:drug effects / Q000502:physiology; D011518:Proto-Oncogene Proteins; D016194:Receptors, N-Methyl-D-Aspartate / Q000187:drug effects / Q000502:physiology; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology; D020521:Stroke / Q000628:therapy*
D016328:NF-kappa B; D018696:Neuroprotective Agents; D011518:Proto-Oncogene Proteins; D016194:Receptors, N-Methyl-D-Aspartate; D004921:Erythropoietin; D009569:Nitric Oxide; D011505:Protein-Tyrosine Kinases; C507924:JAK2 protein, human; D053614:Janus Kinase 2